This document summarizes a study assessing the therapeutic efficacy of chloroquine (CQ) for treating Plasmodium vivax malaria among outpatients in southern Ethiopia. Sixty-three patients with confirmed P. vivax infection were treated with CQ over 3 days and monitored for 28 days. Two patients experienced recurrent parasitemia within 28 days, indicating a 96.7% efficacy of CQ. While CQ showed high efficacy in this study, some previous studies in Ethiopia found increasing chloroquine resistance in P. vivax, highlighting the need for ongoing monitoring of resistance.
Un estudio sobre las caracteristicas del tratamiento sde la TB XDR en sudafrica y el pronostico de vida de los pacientes segun las estrategias terapeuticas
ABSTRACT- Invasive fungal infections have become a major source of morbidity and mortality in post operative
patients. Critically ill patients after extended surgical procedure are more risk to post surgical fungal infections. Life
saving devices like central venous catheters can increases risk for fungal infections. Surgical infections are infections of
the tissues, organs or spaces exposed by surgeons during performances of surgical procedure. Mold infection is
increasingly common in post operative patients. Postoperative surgical infection represents an uncommon but potentially
devastating complication of surgery. Unfortunately, medical community is not much aware of such secondary infections
due to fungi in post operative patients leading to grave consequences. Better diagnostic methods are needed to improve
the outcome of successful surgery and better health care for public. The diagnosis of invasion and dissemination in the
majority of cases requires the acquisition and proper interpretation of clinical evidence.
Key-words- Postoperative, Surgical infections, Secondary infections, Diagnostic method
Fungal infections can occur due to the increasing use of broad-spectrum antibiotics and patients with immunodeficiency. Some pathogens, such as Cryptococcus, Candida,and Fusarium, rarely cause serious diseases in the normal host, while other endemic fungi, such as Histoplasmosis, Coccidiodes,and Paracoccidiodes can cause disease in a normal host, but has a tendency to be aggressive on immunocompromise.
Candida species are normal flora that may be an apportunistic pathogen. Candidiasis occurs in some diseases such as gastrointestinal mucosal esophagitis, a fungal disease associated with the use of catheters and in - patients who have mucosal damage or obtain broad – spectrum antibiotics. Other candidiasis consist of skin candidiasis, funguria candidiasis, disseminated candidiasis and endocarditis candidiasis. Candidemia is the fourth most common cause of nosocomial bloodstream infections in the United States and in many of the developed country. Invasive candidiasis has a significant impact on patient outcomes, and it has been estimated that the mortality of invasive candidiasis is as high as 47%. The mortality rates are 15%-25% for adults and 10%-15% for neonates and children. Diagnostic approach to fungal infection is a priority. The knowledge of the changes in epidemiology and risk factors for fungal infections, has become the main reference to measure optimal treatment of fungal infections.
Un estudio sobre las caracteristicas del tratamiento sde la TB XDR en sudafrica y el pronostico de vida de los pacientes segun las estrategias terapeuticas
ABSTRACT- Invasive fungal infections have become a major source of morbidity and mortality in post operative
patients. Critically ill patients after extended surgical procedure are more risk to post surgical fungal infections. Life
saving devices like central venous catheters can increases risk for fungal infections. Surgical infections are infections of
the tissues, organs or spaces exposed by surgeons during performances of surgical procedure. Mold infection is
increasingly common in post operative patients. Postoperative surgical infection represents an uncommon but potentially
devastating complication of surgery. Unfortunately, medical community is not much aware of such secondary infections
due to fungi in post operative patients leading to grave consequences. Better diagnostic methods are needed to improve
the outcome of successful surgery and better health care for public. The diagnosis of invasion and dissemination in the
majority of cases requires the acquisition and proper interpretation of clinical evidence.
Key-words- Postoperative, Surgical infections, Secondary infections, Diagnostic method
Fungal infections can occur due to the increasing use of broad-spectrum antibiotics and patients with immunodeficiency. Some pathogens, such as Cryptococcus, Candida,and Fusarium, rarely cause serious diseases in the normal host, while other endemic fungi, such as Histoplasmosis, Coccidiodes,and Paracoccidiodes can cause disease in a normal host, but has a tendency to be aggressive on immunocompromise.
Candida species are normal flora that may be an apportunistic pathogen. Candidiasis occurs in some diseases such as gastrointestinal mucosal esophagitis, a fungal disease associated with the use of catheters and in - patients who have mucosal damage or obtain broad – spectrum antibiotics. Other candidiasis consist of skin candidiasis, funguria candidiasis, disseminated candidiasis and endocarditis candidiasis. Candidemia is the fourth most common cause of nosocomial bloodstream infections in the United States and in many of the developed country. Invasive candidiasis has a significant impact on patient outcomes, and it has been estimated that the mortality of invasive candidiasis is as high as 47%. The mortality rates are 15%-25% for adults and 10%-15% for neonates and children. Diagnostic approach to fungal infection is a priority. The knowledge of the changes in epidemiology and risk factors for fungal infections, has become the main reference to measure optimal treatment of fungal infections.
This Manual of Procedures (MOP) was developed to assist and align the efforts in implementing AMS programs in all (Level I, II, and III) hospitals across the country. It seeks to serve as a guide to individual hospitals in the design and establishment of local AMS programs while providing a framework for national-level action and commitment.
Recommendations within this document are, as far as possible, based on review of published literature on strategies that have shown to be effective. Consultation with key members (Infectious Diseases physicians, clinical pharmacists, and Infection Control nurses) from eight (8) pilot hospitals as well as the National Antibiotic Guidelines Committee (NAGCom), other national Infectious Diseases societies and relevant DOH offices were undertaken to obtain a consensus opinion and ensure that this MOP is practical and feasible.
All attempts to consider the context of local culture and practices have been taken in the creation of this MOP. Nonetheless, we have chosen to only define core aspects of the national AMS program without being overly prescriptive. Hospitals are strongly encouraged to adapt this MOP to their individual setting in order to maximize its effectiveness, including reduce barriers to implementation and encourage shared ownership towards the goal of AMS.
This Manual of Procedures (MOP) was developed to assist and align the efforts in implementing AMS programs in all (Level I, II, and III) hospitals across the country. It seeks to serve as a guide to individual hospitals in the design and establishment of local AMS programs while providing a framework for national-level action and commitment.
Recommendations within this document are, as far as possible, based on review of published literature on strategies that have shown to be effective. Consultation with key members (Infectious Diseases physicians, clinical pharmacists, and Infection Control nurses) from eight (8) pilot hospitals as well as the National Antibiotic Guidelines Committee (NAGCom), other national Infectious Diseases societies and relevant DOH offices were undertaken to obtain a consensus opinion and ensure that this MOP is practical and feasible.
All attempts to consider the context of local culture and practices have been taken in the creation of this MOP. Nonetheless, we have chosen to only define core aspects of the national AMS program without being overly prescriptive. Hospitals are strongly encouraged to adapt this MOP to their individual setting in order to maximize its effectiveness, including reduce barriers to implementation and encourage shared ownership towards the goal of AMS.
• Identify and validate customers,count and check cash and cheques.
• Accept cash and cheques for deposit.
• Perform specialized tasks such as preparing cashier’s cheques, personal money orders, issuing traveler’s cheques and exchanging foreign currency.
• Performs services for customers such as ordering bank cards and cheques.
• Received and verify loan payments, mortgage payment and utility bills.
• Record all transaction promptly ,accurately and in compliance with bank procedures.
• Balance currency, cash and checks-in cash drawer at end of each shift.
• Ensure compliance with all internal controls and established policies and procedures.
A Comparative Study of the Efficacy of 5 Days and 14 Days Ceftriaxone Therapy...iosrjce
IOSR Journal of Dental and Medical Sciences is one of the speciality Journal in Dental Science and Medical Science published by International Organization of Scientific Research (IOSR). The Journal publishes papers of the highest scientific merit and widest possible scope work in all areas related to medical and dental science. The Journal welcome review articles, leading medical and clinical research articles, technical notes, case reports and others.
The prevalence of tuberculosis and Rifampicin-resistant tuberculosis (RMP-TB) among patients showing symptoms of tuberculosis that visited Federal Medical Centre, Yenagoa, Bayelsa state, Nigeria was determined from June 2015 to December 2015. A total of 456 patients comprising 218(47.8%) males and 238(52.2%) females were examined using their sputum and gastric lavage samples. GeneXpert System was used to determine the TB and RMF-TB. Results showed that out of the 456 patients, overall tuberculosis prevalence was 88(19.3%), males recorded 48(10.5%) while females had 40(8.8%). The highest tuberculosis prevalence was recorded amongst 21-30 years and 31-40 years age groups (5.5%). Out of the 456 patients, total prevalence for Rifampicin resistance was 11(2.4%). Of these, females and male prevalence was 6(1.3%) and 5(1.1%) respectively. There was no significant difference (P>0.05) in prevalence between age and gender. The treatment and follow-up of existing cases is a key to preventing the spread of multi drug-resistant tuberculosis.
Malaria is still considered globally as a leading cause of morbidity with Nigeria carrying the highest burden of 19%. Coinfection of malaria and Human Immunodeficiency Virus (HIV) accelerate disease progression of HIV/AIDS subjects. This study investigated the prevalence and predictors of malaria among HIV infected subjects attending the antiretroviral therapy Clinic at Federal the Medical Centre, Keffi, Nigeria. After ethical clearance, 200 whole blood specimens were collected from patients who gave informed consent and completed a self-structured questionnaire. The specimens were examined for malarial parasite using rapid kits and microscopy. The overall prevalence of the infection was 78/200 (39.0%). The prevalence was higher in male (44.7%) than female (34.0%) subjects. Those subjects aged < 20 years (54.5), male gender (44.7%), non-formal education holders (61.5%), farmers (62.5%), stream water users (48.1%), those that lives in rural setting (43.6%), those that do not use Insecticides Treated Nets (ITNs) (39.4%) and swampy environment dwellers (41.7%) were identified predictors for malaria infection in the area. All the predictors studied did not show any statistically significant difference with the infection but some arithmetic difference exists (P > 0.05). The 39.0% prevalence of malaria in HIV infected subjects is a public health concern. Therefore, Public health surveillance and health education among HIV population should be advocated to help eradicate malaria comes 2030. Further study that will characterize the genes of the parasite should be carried out.
Comparative study of the effectiveness of combination therapies based on atem...Open Access Research Paper
The National Malaria Control Program recommended in 1993, the use of Chloroquina (CQ) as first line drug for malaria treatment, and sulfadoxin pyrimethamin as second drug. After years, Benin knows resistance about these antimalarials. Quinina was to treat gravities. In 2004, the strategy of treatment changed. Treatment of malaria cases is based on use of arteminisinia therapeutic combination. The goal of this study is to be sure that these drugs are efficace before general use in the country and in some regions as Dassa Zounmè where the resistance is up (61. 3% for Chloroquina CQ and 45.9% for SP in 2002).The study is based on: comparison of therapeutic efficacy of artemether Lumefantrine and Artesunate Amodiaquine. Results show that all of the tested drugs have good therapeutic efficacy. Most important rate failure is in Dassa Zounmè (33, 86%) than Parakou (23, 44%). They are parasitologic failure and are probably due to the reinfestation of children. Two drugs have a good parasitological clearance and eliminate fever after 2 days of treatment.
Adverse Events among HIV/MDR-TB Co-Infected Patients Receiving Antiretroviral...Dr.Samsuddin Khan
Abstract
Background
Significant adverse events (AE) have been reported in patients receiving medications for multidrug- and extensively-drug-resistant tuberculosis (MDR-TB & XDR-TB). However, there is little prospective data on AE in MDR- or XDR-TB/HIV co-infected patients on antituberculosis and antiretroviral therapy (ART) in programmatic settings.
Methods
Médecins Sans Frontières (MSF) is supporting a community-based treatment program for drug-resistant tuberculosis in HIV-infected patients in a slum setting in Mumbai, India since 2007. Patients are being treated for both diseases and the management of AE is done on an outpatient basis whenever possible. Prospective data were analysed to determine the occurrence and nature of AE.
Results
Between May 2007 and September 2011, 67 HIV/MDR-TB co-infected patients were being treated with anti-TB treatment and ART; 43.3% were female, median age was 35.5 years (Interquartile Range: 30.5–42) and the median duration of anti-TB treatment was 10 months (range 0.5–30). Overall, AE were common in this cohort: 71%, 63% and 40% of patients experienced one or more mild, moderate or severe AE, respectively. However, they were rarely life-threatening or debilitating. AE occurring most frequently included gastrointestinal symptoms (45% of patients), peripheral neuropathy (38%), hypothyroidism (32%), psychiatric symptoms (29%) and hypokalaemia (23%). Eleven patients were hospitalized for AE and one or more suspect drugs had to be permanently discontinued in 27 (40%). No AE led to indefinite suspension of an entire MDR-TB or ART regimen.
Conclusions
AE occurred frequently in this Mumbai HIV/MDR-TB cohort but not more frequently than in non-HIV patients on similar anti-TB treatment. Most AE can be successfully managed on an outpatient basis through a community-based treatment program, even in a resource-limited setting. Concerns about severe AE in the management of co-infected patients are justified, however, they should not cause delays in the urgently needed rapid scale-up of antiretroviral therapy and second-line anti-TB treatment
Adherence to Antiretroviral Therapy among HIVPositive Patients in Central Hos...Efe Clement Abel
Abstract: Adherence is the quantified level to which an individual follows a prescribed treatment and a low level of adherence to antiretroviral therapy(ART) adversely affects a patient’s treatment outcome and results in a rebound of plasma viraemia, development of resistant strains of HIV, more rapid immune deterioration, development of AIDS and death. This study is aimed at assessing the level of adherence to ART among HIV-positive patients assessing care in Central Hospital, Warri, Delta State, Nigeria. A descriptive cross-sectional study. Data were obtained using a semi-structured, interviewer-administered questionnaire and analysed using SPSS version 23. A total of 303 persons were recruited for the study. The mean age of respondents was 36.2±10.8years. Less than half of the subjects (45.5%) were adherent to their ART. Among the non-adherent subjects, the common reasons reported for missing doses of ART were forgetfulness (50.9%), too busy with other things (43.6%) and away from home (35.8%). This study showed that adherence to ART among the study population was poor. Forgetfulness, too busy with other things and being away from home were the most common reason for non-adherence. It is, therefore, recommended that; regular health education should be organised for HIV patients on ART on the importance of being adherent to their ART, regular assessment of adherence to ART should be carried out and a method of reminding patients who are non-adherent to ART on the need to take their ART as at when due should be considered as part of the routine services provided by ART centres.
Malaria Control Strategies among Rural Dwellers in a Typical Nigerian Settingasclepiuspdfs
Malaria is a major public health problem in sub-Saharan African, including Nigeria, causing 63% of total outpatient attendance in health facilities, 30% under-five mortality, and 11% of maternal mortality. Malaria control practices remain a major strategy in the combat of this menace. Therefore, the aim of this study is to determine the malaria control strategies utilized among rural dwellers in the Ezza North local government area (LGA) of Ebonyi state.
Factors Associated with patients adherence to Tb treatment following COVI-19 ...MtMt37
studies show that, Poor adherence to treatment is one of the major challenges affecting tuberculosis control and account for the major obstacles to treatment management . Uganda had a TB default rate of 11% with a treatment success rate of only 70% among smear positive patients (WHO, 2010), compared with national accepted adherence level of 95% of as per the WHO guidelines. It is on record that, Masaka District has high prevalence of TB known to be associated with HIV/AIDs (NTRL 2016). an institutional based survey established among other factors that, inadequate and irregular supplies of TB drugs, long travel distance by patients, stigma, discrimination and suspension of transport as COVID 19 prevention guideline have contributed to poor adherence of TB patients in Masaka.
2. Page 2 of 8Assefa et al. Malar J (2015) 14:458
respectively, has worsened the problem of control [3].
Chloroquine (CQ) is the cheapest anti-malarial drug
available at peripheral level (sub-health post and health
post without laboratory facilities). It is used for treatment
of laboratory-confirmed Plasmodium vivax and sympto-
matic malaria [4]. However, some studies revealed that
the emergence of chloraquine-resistant (CQR) strains of
P. vivax has been alarming and affected endemic coun-
tries, such as Ethiopia [5–8], Madagascar [9], Myan-
mar [10], and Indonesia [11]. High levels of CQR on the
northern part of the islands of New Guinea and Sumatra,
Indonesia have been well documented, as well as spo-
radic reports from other locations [12].
The World Health Organization (WHO) recommended
that drug efficacy be regularly assessed. Failure to detect
the emergence of anti-malarial drug resistance could lead
to a drug-resistant malaria epidemic which would have
major public health and economic consequences for an
area, province and country [3, 13, 14]. Therefore, moni-
toring of drug resistance is essential for timely changes
to treatment policy, which should be initiated when the
treatment failure rate exceeds 10 % at the end of follow-
up [13]. However, a decision to change treatment policy
may be influenced by a number of additional factors,
including the prevalence and geographical distribution of
reported treatment failures, health service provider and/
or patient dissatisfaction with the treatment, the political
and economic context, and the availability of affordable
alternatives to the commonly used treatment [15].
Emergence and the spread of CQR P. vivax strains is
becoming a major public health problem in different
countries, and requires regular monitoring to control
its spread [1]. There are a few reports of CQR P. vivax in
different parts of Ethiopia [6–8]. Such evidence neces-
sitates a need for urgent assessment to obtain informa-
tion in order to develop or change treatment policies [3,
13]. This study was conducted to assess the therapeutic
efficacy of CQ for the treatment of vivax malaria among
outpatients at Hossana Health Care Centre, southern
Ethiopia.
Methods
Study site and population
The study was conducted in Hadiya Zone, Hossana Town,
which is located in the Ethiopian Rift Valley (Fig. 1), in
the north-western part of Southern Nation’s Nation-
alities and Peoples’ Region (SNNPR), 230 km south of
Addis Ababa and 145 km from Hawassa. The town lies at
a longitude of 10°060 N 39°590 E and latitude of 10.1°N
39.983° E. The town has a total of 104,208 inhabitants.
The area has a short rainy season from March to May and
a high rainfall during the main season (June–September)
and is characterized by unstable and seasonal malaria,
one of the main diseases in the town and its surround-
ings, that occurs with peak transmission following the
rainy seasons [17].
The study participants were patients with confirmed P.
vivax mono-infection on thick and thin blood film prepa-
rations and who fulfilled the inclusion criteria [13] and
were seeking treatment at Hossana Health Centre during
the study period. The source population were those clini-
cally malaria-suspected individuals with fever or history
of fever seeking treatment at Hossana Health Care Cen-
tre during the study period.
The inclusion criteria included age over 6 months,
mono-infection with P. vivax detected by micros-
copy, asexual parasite count >250/μl, axillary tempera-
ture ≥37.5 °C or history of fever during the previous
48 h, ability to swallow oral medication, willingness
to comply with the study for the duration of the study,
informed consent from the patient or parent/guardian
in the case of children [3, 13]. Participants who were
infected with vivax malaria requiring hospitalization,
or had severe malnutrition, febrile condition due to
diseases other than malaria, regular medication which
might interfere with anti-malarial pharmacokinetics,
were pregnant and breastfeeding, were excluded from
the study [3, 13].
The required sample size was calculated based on the
prevalence of 3.6 % treatment failure in a study con-
ducted in Serbo Town [7], 5 % precision, 95 % confidence
level. An additional 20 % (10 patients) were expected loss
to follow-up rate and withdrawal of consent during the
study, and therefore 63 participants were included.
Study design
A one-arm, prospective evaluation of clinical and para-
sitological responses to directly observed treatment for
vivax malaria was used. Patients with P. vivax infection,
who fulfilled the inclusion criteria were enrolled, treated
and followed for 28 days. The follow-up included a fixed
schedule (1, 2, 3, 7, 14, 21, and 28 days) of check-up visits
and corresponding clinical and laboratory examinations
[13].
Questionnaires were used to gather general informa-
tion such as socio-demographic information from study
participants by senior laboratory technologists and
checked by the principal investigator for completeness.
Clinical and laboratory information were collected as
follows:
Treatment and follow‑up
A 28-day, in vivo, drug efficacy testing was done accord-
ing to methods recommended by WHO [16] and the
Ethiopian Ministry of Health [17]. Patients were treated
with a 25 mg/kg CQ-sulfate (Addis Pharmaceuticals,
3. Page 3 of 8Assefa et al. Malar J (2015) 14:458
Adigrat, batch number 9461, date 02/2011 and expira-
tion 02/2016), administered for three consecutive days
(10, 10 and 5 mg/kg on days 0, 1 and 2, respectively) [4,
18, 19] at Hossana Health Care Centre. All doses were
administered under direct observation. Study subjects
were checked for vomiting for 30 min after intake of the
drug; those who vomited were retreated with the same
dose. Subjects who vomited twice were excluded from
the study. The study participants were advised not to take
other drugs, except for patients with axillary tempera-
ture >37.5 °C who were treated with paracetamol (10 mg/
kg). Patients were advised to come back to the Health
Care Centre if they felt sick at any time during the follow-
up period for clinical and parasitological examination. In
particular, parents or guardians were instructed to bring
children to the Health Care Centre at any time if they
showed any sign of danger (unable to drink or breast-
feed, vomiting, presenting with convulsions, lethargic or
unconscious, unable to sit or stand, presenting with dif-
ficult breathing) [13].
Patients who met all the inclusion criteria were given
a personal identification number and received treatment
only after the study was fully explained and informed
consent provided. Patients who decided to participate in
the study were examined, treated and followed. Succes-
sive monitoring of parasitological and clinical responses
was made on the follow-up days to each patient until
day 28. The day a patient was enrolled and received the
first dose of CQ was designated as day 0. Patients were
informed to come for follow-up on days 1, 2, 3, 7, 14, 21,
and 28. Thick and thin blood smears were prepared and
examined for checking parasite clearance and/or recur-
rence of parasitaemia at all follow-up visits. Haemoglo-
bin measurement was made on days 0 and 28 during
follow-up and on day of recurrence of parasitaemia. Any
patient who did not come to the Health Care Centre on
the day of appointment was traced at his/her home and
assisted by the health extension workers to complete the
follow-up.
Clinical procedures
Physical examinations such as the auxiliary tempera-
ture, weight and clinical conditions were done during the
study period for all study participants.
Fig. 1 Map of the study area
4. Page 4 of 8Assefa et al. Malar J (2015) 14:458
Laboratory procedures
Capillary blood was collected from each study partici-
pant; duplicate thick and thin blood films were made
at recruitment and on each follow-up days. The blood
films were stained with stained with 10 % Giemsa for
10 min, examined with100X oil immersion objective.
Species identification and parasite quantification was
done by trained senior medical laboratory technologist
and reports were recorded on the laboratory request.
The thick blood smears were used to count the num-
bers of asexual parasites and white blood cells (WBCs)
in a limited number of microscopic fields. Plasmodium
vivax asexual stages were counted against 200 WBCs.
Parasitaemia was determined according to formula
below [13].
Haemoglobin was measured on days 0 and 28 during
follow-up for each study participants and on day of recur-
rence of parasitaemia. Finger-pricked blood was taken
and read by portable spectrophotometer (HemoCue Hb
301 System, Sweden). Anaemia was defined according to
[20] categorization.
Urine of all female participants was screened for preg-
nancy by Strip Test, (PR China, date 2012/11, Expiration
2014/11, Batch number W00121125.2) and those testing
positive were excluded from the study.
Study endpoints
Study participants were classified either as ‘adequate clin-
ical and parasitological responses’, in the absence of para-
site recurrence within 28 days of follow-up, or ‘treatment
failure’ in case of recurrence of parasitaemia during fol-
low-up and new infection with Plasmodium falciparum
(within 28 days).
Statistical analysis
Statistical Package for Social Science (SPSS) version
16 was used for data management and analysis. Data of
patients having mixed infection with P. falciparum, lost
to follow-up and vomiting were excluded from the analy-
sis according to WHO method. The analysis included the
proportion of early treatment failure (ETF), late clini-
cal failure (LCF), late parasitological failure (LPF), and
adequate clinical and parasitological response (ACPR)
at day 28. Kaplan–Meier survival estimate was used to
evaluate risk of therapeutic failure in study participants
during follow-up period. Change in mean haemoglobin
level on days 0 and 28 was compared using paired t test.
In not normally distributed data for example age; median
Parasite density (per µl of blood)
=
WBC (8000) × Number of asexual parasites counted
Number of WBC counted (200)
value was used to measure the central tendency. Parasite
counts were made using geometric mean. In all analysis,
p value <0.05 was considered significant.
Ethical consideration
The study was reviewed and approved by the Ethical
Review Committee of Jimma University, College of Public
Health and Medical Sciences. Permission was obtained
from Hadiya Zone Health Office, Hossana Town Admin-
istration Health Office and Hossana Health Centre. The
purpose of the study was explained and written informed
consent was obtained from each participant and parents
or guardians of children.
Data quality control
Data collectors were trained by diagnostic senior experts
from the regional referral laboratory, including the prin-
cipal investigator before the actual work. Competency
of the data collectors was assessed and selected for the
study. Standard operating procedures were strictly fol-
lowed. Quality of reagents and equipment was checked
each day the diagnosis of the patient sample. All P. vivax-
positive slides on day of admission, all slides on day of
recurrence and 5 % of negative slides were picked ran-
domly from slides prepared during follow-up and were
re-examined blind by experts from the regional referral
laboratory.
Results
Of a total of 1693 patients screened for malaria at Hos-
sana Health Care Centre, 1,412 were negative and 281
were positive for malaria. Among all positive patients,
182 were P. falciparum, 92 P. vivax and seven were
mixed infection. From 92 P. vivax-positive patients,
63 who fulfilled the inclusion criteria were recruited.
Twenty-nine patients were excluded from the study
before enrolment as they did not fulfil the inclusion
criteria, and of these, 13 were excluded due to long dis-
tance from the health centre, seven were pregnant, six
had prior anti-malarial intake and three refused con-
sent. From the 63 study participants, three patients
were excluded from the study: one participant vomited
twice during the third dose of CQ at day 2, the second
participant was found infected by P. falciparum asexual
stage on day 14, and the third patient was lost to follow-
up on day 14; the remaining 60 participants completed
the 28-day follow-up (Fig. 2).
Among the recruited study participants, males were
higher in proportion compared to females, (35 and 25,
respectively). The median age of study participants was
23 (range 4–59) (Table 1). Among the study partici-
pants, 32 (53.3 %) had a history of fever and 28 (46.7 %)
5. Page 5 of 8Assefa et al. Malar J (2015) 14:458
had fever at the time of enrolment. The duration of ill-
ness of the patients before enrolment was 3.05 ± 1.41
(mean ± SD) days. The geometric mean of parasite at day
0 was 3472.1 parasites/μl.
Based on therapeutic failure risk calculated by
the Kaplan–Meier survival analysis, the number of
patients at risk on day 0 was 63, but this was attributed
to only two patients with treatment failure for 28-day
study. Among the 60 patients, 100 % parasite clear-
ance was observed by day 21. However, in two patients
(3.3 %) CQ treatment failure was observed during
the follow-up period. This was observed in 10 and
14 years old children on days 28 and 21, respectively.
This places the risk of CQ failure until day 28 at 3.3 %
(Table 2).
Fig. 2 Flow chart of patients’enrolment and follow up for CQ therapeutic efficacy study at Hossana Health Care Centre Southern Ethiopia from
April to June, 2014
0
500
1000
1500
2000
2500
3000
3500
4000
Day 0 Day 2 Day 3 Day 7 day 14 Day 21 Day 28
Geometricmeanofparasites/µl
Geometric mean of parasites
Fig. 3 Parasite clearance following CQ treatment of Plasmodium vivax
infected malaria patients at Hossana Health Care Centre Southern
Ethiopia from April to June, 2014
6. Page 6 of 8Assefa et al. Malar J (2015) 14:458
Parasite and fever clearance
Parasitaemia clearance time was 72 h for all patients
involved in the 28-day follow up in vivo study. At day 0
before drug administration, the geometric mean of para-
sitaemia of the study participants was 3708 parasites/μl of
blood (maximum 10,720 parasites/μl, minimum 1600 par-
asites/μl). The mean body temperature (in °C) from day
of recruitment (day 0) was 37.7, 37.26, 37.0, 36.8, 36.57,
36.37, 36.10, and 35.99 °C for days 0, 1, 2, 3, 7, 14, and 28,
respectively. Thus, mean body temperature of the study
participants at the time of enrolment was 37.7 °C (mini-
mum 36.5 °C, maximum 39.1 °C). Among the study par-
ticipants, 32 (53.3 %) had a history of fever and 28 (46.7 %)
had fever at the day of enrolment. All study participants
cleared fever (mean body temperature on day 2 was
37.0 °C) following parasitaemia clearance (Figs. 3 and 4).
Efficacy outcomes
The mean parasitaemia was 3708.15 parasites/µl of blood
while the mean haemoglobin was 11.5 mg/dl on day of
recruitment. Following CQ treatment, parasitaemia and
fever of study participants were cleared and the mean
haemoglobin concentration was improved (13.4 mg/dl).
In this study, there were no early treatment failure and
late clinical failures but two (3.3 %) LPFs were observed
at the end of the study (on days 21 and 28). The ACPR
after the 28-day follow-up was 58 (96.7 %).
Haemoglobin recovery
On day of enrolment, 30 (50 %) patients were found to
have mild anaemia: one patient was found to have mod-
erate anaemia, no patients had severe anaemia and 29
(48.3 %) were non-anaemic (haemoglobin value ≥12 g/
dl). On the other hand, a significant (p = 0.01) increase
was observed in the haemoglobin level between the
baseline and day 28. Among the study participants with
ACPR, 52 (86.7 %) were non-anaemic and eight (13.3 %)
had mild anaemia. The mean haemoglobin concentra-
tion of study participants at day of enrolment was 11.5 g/
dl (ranging from 9.9 to 13.2 g/dl) and 13.4 g/dl (ranging
from 10 to 14 g/dl) on day 28 (Table 3).
Table 1 Socio-demographic characteristics of patients
enrolled in the in vivo therapeutic efficacy study of CQ
for Plasmodium vivax malaria at Hossana Health Care Cen-
tre Southern Ethiopia from April to June 2014
Socio-demographic variables Total no. (%)
Age (in years)
Median 23
Range 4–59
Gender
Male 35 (58.3)
Female 25 (41.7)
Ethnicity
Hadiya 40 (66.7)
Kembata 11 (18.3)
Gurage 7 (11.7)
Silte 2 (3.3)
Occupation
Government employee 2 (3.3)
Unemployed 3 (5.0)
Student 27 (45.0)
House wife 15 (25.0)
Farmer 8 (13.8)
Daily laborer 4 (6.7)
Others 1 (1.7)
Marital status
Single 28 (46.7)
Married 31 (51.7)
Widowed 1
Table 2 Kaplan–Meier survival estimate of risk of thera-
peutic failure of CQ for the treatment of Plasmodium
vivax, at Hossana Health Care Centre Southern Ethiopia
from April to June, 2014
D N TF Ex IRD FCID
Day 0 63 0 0 1.000 0
Day 1 63 0 0 1.000 0
Day 2 63 0 1 1.000 0
Day 3 62 0 0 1.000 0
Day 7 62 0 0 1.000 0
Day 14 62 0 2 1.000 0
Day 21 60 1 0 0.983 0.017
Day 28 59 1 0 0.967 0.033
Total 2 3
Fig. 4 Fever clearance following CQ treatment of Plasmodium vivax
infected malaria patients at Hossana Health Care Centre Southern
Ethiopia from April to June, 2014
7. Page 7 of 8Assefa et al. Malar J (2015) 14:458
Discussion
CQ has been in use both for treatment and prophylaxis in
health institutions in Ethiopia. It is the anti-malarial drug
recommended as first-line treatment for vivax malaria by
the Federal Ministry of Health, Ethiopia [18]. However,
there are some alarming reports on CQR vivax malaria
from different malaria-endemic areas of Ethiopia [5–8]. It
is becoming a major public health problem that requires
rapid and effective management to control the spread of
resistance, which requires proper diagnosis of cases and
administration of effective anti-malarial drugs [13].
The present study showed the prevalence of falciparum
and vivax malaria at Hossana Health Care Centre, south-
ern Ethiopia. Plasmodium falciparum-infected patients
were detected more frequently than P. vivax patients dur-
ing enrolment of study participants. Out of 282 malaria-
positive patients, 182 were P. falciparum patients, 92 had
P. vivax infections, and seven had mixed infections. A
report from Hossana Town health office showed that in
previous reports P. falciparum is more prevalent than P.
vivax, which supports this recent study.
This study, a 28-day, in vivo, therapeutic efficacy test
on CQ undertaken at Hossana Health Care Centre has
demonstrated two (3.3 %) LPFs. The low level of treat-
ment failure detected in the present study was compara-
ble with previous reports from different parts of Ethiopia.
Debrezeit 2 % [5], Serbo 3.6 % [7], However, the result of
this study was relatively lower when compared with high
treatment failures reported from Halaba Special Woreda
in southern Ethiopia, 11.7 % [8].
In the current study, two patients with CQ treatment
failure were children aged 10 and 14 years, which is a
similar condition to cases of treatment failure observed
by studies conducted in Debrezeit and Serbo towns in
Ethiopia [6, 7], in India [21] and in Indonesia [11] .
Decreased parasite density on day of recurrence was
observed in this study in one patient, unlike studies done
elsewhere [7, 22, 23]. Based on WHO guidelines for
therapeutic efficacy study of anti-malarials, resistance is
classified as ETF, LCF, LPF, or ACPR. Accordingly, this
study revealed two patients with LPF, which is defined as
presence of parasitaemia on any day from day 7 to 28 and
axillary temperature <37.5 °C, without previously meet-
ing any of the criteria of ETF or LCF [24, 25].
Anaemia is a major effect of malaria infection. During
intra-erythrocytic development, malaria trophozoites
digest haemoglobin. Thus, treatment with the appropri-
ate drug is expected to improve patients’ haemoglobin
level with time [25]. In this study, significant increase
in haemoglobin concentration (p = 0.01) was observed
from baseline to day 28 among patients with ACPR. In
addition, one patient with treatment failure showed
improvement of haemoglobin value on the day of recur-
rence. However, one patient with treatment failure had
no haemoglobin improvement on the day of recurrence.
This study showed two (3.3 %) CQ treatment failures of
vivax malaria at Hossana Health Care Centre, southern
Ethiopia. However, the rate of resistance was lower com-
pared to a previous study elsewhere in Ethiopia, which
was 13.7 % [8]. It is important to caution responsible
authorities to extend efforts to monitor drug resistance
and treatment failure problems in all malaria-endemic
parts of the country. According to WHO first-line treat-
ment of malaria should be changed if the total failure rate
exceeds 10 % [13]. It is important to survey CQ treatment
failures and intervene before the level is reached that pre-
sents a public health problem.
Conclusions
The three-dose regimen of CQ showed therapeutic effi-
cacy (96.7 %) in the treatment of uncomplicated vivax
malaria among study patients at Hossana Health Care
Centre, southern Ethiopia. A 3.3 % CQ treatment failure
detected in this study is LTF. Rapid clearance of fever and
asexual parasitaemia was observed after CQ treatment
of uncomplicated vivax malaria. Improvement in mean
haemoglobin level was achieved following CQ treat-
ment from day 0 to 28. Regular monitoring of the pattern
of resistance to CQ is needed in vivax malaria-endemic
areas of the country, and measures be taken rapidly and
effectively to control the spread of resistance. Proper
instruction and utilization of CQ should be exercised in
Table 3 Recovery of haemoglobin concentration observed in Plasmodium vivax infected study participants following CQ
treatment at Hossana Health Centre, Southern Ethiopia from April to June 2014
Hb Age in years (D0) Total Age in years (D28) Total
1–4 5–14 >15 1–4 5–14 >15
Mild 0 9 (30 %) 21 (70 %) 30 (50 %) 0 4 (50 %) 4 (50 %) 8 (13.3 %)
Moderate 0 1 (1.6) 0 1 0 0 0 0
Sever 0 0 0 0 0 0 0 0
Non anemia 1 (3.4 %) 6 (20.7 %) 22 (75.9 %) 29 (48.3 %) 1 (1.9 %) 12 (23.1 %) 39 (75 %) 52 (86.7 %)
8. Page 8 of 8Assefa et al. Malar J (2015) 14:458
order to avoid resistance. The prevalence of falciparum
and vivax malaria observed in the study area requires
strong malaria intervention measures.
Authors’contributions
MA, TE and AB conceived the research, designed the laboratory works and
critically reviewed the manuscript. All authors read and approved the final
manuscript.
Author details
1
Hossana Health Care Centre, Southern Nations, Nationalities, and Peoples’
Region, Hossana, Ethiopia. 2
Department of Medical Laboratory Sciences
and Pathology, Jimma University, P.O.Box: 878, Jimma, Ethiopia.
Acknowledgements
The authors would like to acknowledge Jimma University for financial
assistance.
Competing interests
The authors declare that they have no competing interests.
Received: 1 June 2015 Accepted: 3 November 2015
References
1. WHO. World malaria report. Geneva: World Health Organization; 2013.
2. Federal Ministry of Health. National malaria guidelines. Ethiopia: Addiss
Ababa; 2012.
3. WHO. Monitoring antimalarial drug resistance. Geneva: World Health
Organization; 2001.
4. DACA. Standard treatment guidelines for health centers. Ethiopia: Addiss
Ababa; 2010.
5. Tulu AN, Roger H, Webbeg, Strong JA, Schellenberg, Bradley DJ. Failure
of chloroquine treatment for malaria in the highlands of Ethiopia. Trans R
Soc Trop Med. 1996;90:556–7.
6. Teka H, Petros B, Yamuah L, Tesfaye G, Elhassan I, Muchohi S, et al.
Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia.
Malar J. 2008;7:220.
Additional file
Additional file 1. WHO haemoglobin threshold used to define anaemia
in different age and gender groups [19].
7. Ketema T, Bacha K, Birhanu T, Petros B. Chloroquine-resistant Plasmodium
vivax malaria in Serbo town, Jimma zone, south-west Ethiopia. Malar J.
2009;8:177.
8. Ketema T, Getahun K, Bacha K. Therapeutic efficacy of chloroquine for
treatment of Plasmodium vivax malaria cases in Halaba district, South
Ethiopia. Parasit Vectors. 2011;4:46.
9. Barnadas C, Ratsimbasoa A, Tichit M, Bouchier C, Jahevitra M, Picot S,
et al. Plasmodium vivax resistance to chloroquine in Madagascar: clinical
efficacy and polymorphisms in pvmdr1 and pvcrt-o genes. Antimicrob
Agents Chemother. 2008;52:4233–40.
10. Fryauff DJ, Tuti S, Mardi A, Masbar S, Patipelohi R, Leksana B, et al.
Chloroquine-resistant Plasmodium vivax in transmigration settlements of
West Kalimantan, Indonesia. Am J Trop Med Hyg. 1998;59:513–8.
11. WHO. Monitoring resistance of P. falciparum and P. vivax to anti-malarial
drugs in the Greater Mekong Sub-region. Phuket, Thailand. 2007.
12. WHO. Methods for surveillance of antimalarial drug efficacy. Geneva:
World Health Organization; 2009.
13. WHO. World malaria report. Geneva: World Health Organization; 2011.
14. Federal Ministry of Health. National five year strategic plan for malaria
prevention and control in Ethiopia 2006–2010. Ethiopia: Addis Ababa;
2006.
15. WHO. Monitoring anti-malarial drug resistance. Report of a WHO Consul-
tation. Geneva: World Health Organization. 2001.
16. Federal Ministry of Health. National malaria guidelines. 3rd ed. Ethiopia:
Addis Ababa; 2012.
17. DACA. Standard treatment guideline for general hospitals. Ethiopia: Addis
Ababa; 2010.
18. Federal Ministry of Health. National malaria guidelines. Ethiopia: Addis
Ababa; 2012.
19. WHO. Haemoglobin concentrations for the diagnosis of anaemia and
assessment of severity. Vitamin and mineral nutrition information system.
Geneva: World Health Organization. 2011.
20. Shah I. Chloroquine resistant vivax malaria in an infant: a report from
India. J Vector Borne Dis. 2008;45:176–7.
21. Soto J, Toledo J, Gutierrez P, Luzz M, Llinas N, Cedeno N, et al. Plasmodium
vivax clinically resistant to chloroquine in Colombia. Am J Trop Med Hyg.
2001;65:90–3.
22. Baird JK. Resistance to therapies for infection by Plasmodium vivax. Clin
Microbiol Rev. 2009;22:508–34.
23. WHO. Guidelines for the treatment of malaria. Geneva: World Health
Organization. 2006.
24. WHO. Global report on antimalarial drug efficacy and drug resistance:
2000–2010. Geneva: World Health Organization. 2010.
25. Moore R, Fujioka H, Williams PS, Chalmers JJ, Grimberg B, Zimmerman PA,
et al. Hemoglobin degradation in malaria-infected erythrocytes deter-
mined from live cell magnetophoresis. FASEB J. 2006;20:747–9.
Submit your next manuscript to BioMed Central
and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at
www.biomedcentral.com/submit